Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ERC Advanced Grant for Meinrad Busslinger

04.11.2011
Meinrad Busslinger, Senior Scientist at the Research Institute of Molecular Pathology (IMP) in Vienna, has been selected to receive an Advanced Investigator Grant by the European Research Council ERC. The grant is worth just under 2.5 Million Euro and will be paid out over a period of five years. It will fund the project “LymphoControl” that investigates the development of immune cells.

ERC Advanced Grants allow exceptional established research leaders to pursue ground-breaking, high-risk projects that open new directions in their respective research fields or other domains. They have been awarded for the fourth time this year. 2284 applications were submitted following the last call.

The grant will fund a project entitled "Transcriptional networks controlling lymphocyte development", or “LymphoControl” in short. The aim of the project is to elucidate how transcription factors regulate the development of B- and T-lymphocytes. These white blood cells are the main players in the body’s adaptive immune system.

They are derived from stem cells in the bone marrow and undergo several stages of differentiation before becoming fully functional, mature lymphocytes of the B- or T-cell lineage. Transcription factors are regulatory proteins encoded in the genome that control key stages in this process. Deregulation of the transcriptional control can severely disrupt the programmed cell fate and cause certain types of blood cancer.

Meinrad Busslinger has a long record in immunological research. He was the first to identify a critical factor, named Pax-5, which activates a B cell specific program in the precursor cells and suppresses alternative pathways. Pax-5 is also involved in the development of acute lymphoblastic leukemia in humans.

The project “LymphoControl” will build on previous research efforts, such as the creation of transgenic mice that carry molecular “tags” at the ends of transcription factors.

Busslinger is excited about the European commitment to basic research: “The ERC grant will allow us to carry out a project which requires massive human and technical resources. We have already established the required know-how and infrastructure, owing to the Austrian Science Fund and our sponsor Boehringer Ingelheim. Now we can really take full advantage of the exceptional facilities at the IMP.” The grant will also open career-paths for young researchers. Six additional scientists will be employed under the ERC-funded project.

Meinrad Busslinger was born in Switzerland in 1952. He studied Biochemistry at the ETH Zurich and obtained a doctorate in molecular biology from the University of Zurich. Following postdoctoral studies at the MRC Institute Mill Hill, London, he became a group leader at the University of Zurich. In 1987, he followed Max Birnstiel to the newly founded Research Institute of Molecular Pathology (IMP) in Vienna.

Busslinger is a Senior Scientist and Director of Academic Affairs at the IMP, Professor at the University of Vienna and a full member of the Austrian Academy of Sciences and of the European Molecular Biology Organisation EMBO. He has published over 130 papers in peer-reviewed journals and serves on the editorial boards of several scientific journals. Busslinger was awarded the Wittgenstein prize of the Austrian government in 2001 and the Virchow Medal by the University of Würzburg in 2010.

The recent allocation raises the number of ERC Grants awarded to IMP faculty to six: Barry Dickson succeeded in securing an advanced grant in the first round of evaluations in 2008. Stefan Westermann, Alexander Stark, Andrew Straw and Manuel Zimmer received ERC Starting Grants.

The Research Institute for Molecular Pathology carries out basic biomedical research in Vienna, Austria. Its main sponsor is Boehringer Ingelheim. Some 200 researchers from over 30 countries study life at molecular and cellular levels, information processing and storage in neural circuits, mechanisms of development and disease and interdisciplinary topics. The aim is a thorough understanding of complex biological processes that could lead to the development of new therapeutic concepts.

Contact:
IMP – Research Institute of Molecular Pathology
Dr. Heidemarie Hurtl, Communications
Tel. +43 1 797 30 – 3625
Mobile:+43 (0)664 8247910
hurtl@imp.ac.at
Scientific Contact
Prof. Meinrad Busslinger
busslinger@imp.ac.at

Dr. Heidemarie Hurtl | idw
Further information:
http://www.imp.ac.at/research/research-groups/busslinger-group/

More articles from Awards Funding:

nachricht Helmholtz International Fellow Award for Sarah Amalia Teichmann
20.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Scientist from Kiel University coordinates Million Euros Project in Inflammation Research
19.01.2017 | Christian-Albrechts-Universität zu Kiel

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>